Johnson & Johnson 3Q Innovative Medicine Sales Growth Partly Offset

Johnson & Johnson said third-quarter Innovative Medicine operational sales growth was partly offset by the impact of Stelara, Simponi and Simponi Aria, Remicade, Opsumit and Opsynvi, and Imbruvica.